The hepatorenal syndrome.
HRS occurs frequently in patients with advanced cirrhosis of the liver and fulminant hepatitis. The pathogenesis of HRS is not clearly understood; reduced effective plasma volume and intense renal cortical vasoconstriction seem to have important roles. The HRS is a diagnosis by exclusion, and it [table: see text] is often difficult to differentiate this entity from prerenal azotemia and ATN. The HRS is characterized by its relentless progression and usually fatal outcome. The essential steps in the management of HRS are to identify and correct the precipitating factors leading to HRS and avoidance of potential hepatotoxic and nephrotoxic drugs. Patients with potentially reversible liver diseases should be treated aggressively. Volume expansion is important and should be tried first, even though hypovolemia may be not clinically evident. Dialysis may benefit patients with fluid overload and electrolyte imbalance or those awaiting liver transplantation. In selective cases, peritoneovenous shunt may be of value. Liver transplantation is the only curative therapy available at present.
Punukollu
R C
RC
Wright State University, Dayton, Ohio.
Gopalswamy
N
N
D000818:Animals; D001202:Ascitic Fluid; D003937:Diagnosis, Differential; D004322:Drainage; D005355:Fibrosis / Q000150:complications; D006439:Hemodynamics; D006530:Hepatorenal Syndrome / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D007668:Kidney / Q000473:pathology; D007674:Kidney Diseases / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D016031:Liver Transplantation; D010536:Peritoneovenous Shunt; D006435:Renal Dialysis